Abu Dhabi: In a regional first, the Imperial College London Diabetes Centre (ICLDC), part of the M42 group, announced it would open a dedicated one-stop facility in Madinat Zayed to provide comprehensive care for diabetes and endocrine patients. With a proven track record of nearly two decades, ICLDC's model for diabetes prevention and management has significantly reduced HbA1c values in patients across the UAE. The new tech-enabled, world-class centre in Al Dhafra will serve a critical part of Abu Dhabi's population, providing targeted prevention and intervention for more than 6,000 diabetes sufferers.
Set to open in the second half of this year, the state-of-the-art facility will bring comprehensive care closer to those in need and cut travel time by more than 75%. Currently, the flagship ICLDC in Abu Dhabi serves around 9% of the suffering population of Al Dhafra. The new facility in Madinat Zayed will provide greater access to sufferers across the Al Dhafra region, including residents in Liwa, Mirfa, Gayathi, Ruwais, and Tarif.
In addition to providing clinical care, ICLDC will continue to promote preventive solutions for Type 2 diabetes. This includes an extensive community outreach program, workshops, health screenings, educational programs for schools and organisations, and promoting an active lifestyle and healthy eating.
Hasan Jasem Al Nowais, Managing Director and Group Chief Executive Officer, M42, said: "M42 is committed to providing world-class preventive and personalised health solutions that enable individuals to put their health back in their own hands. As a leader in diabetes and endocrine management and prevention, the Imperial College London Diabetes Centre positively impacts lives across the UAE. Expanding our one-stop services to Al Dhafra presents an opportunity to serve a much greater number of UAE residents with an innovative model that provides premium, tech-enabled health solutions that result in tangible positive clinical outcomes."
ICLDC has played a vital role in revolutionising population health in the UAE over the past twenty years. It has led to a notable decrease in HbA1c levels, dropping from an average of 9.5% to an impressive 7.2% among its patients. A remarkable 57% of ICLDC's patients now have HbA1c results below 7%, surpassing the international benchmark of 38%. These exceptional outcomes demonstrate the expertise and commitment of the team of over 65 consultants in diabetes and endocrine care across ICLDC's facilities.
The new Al Dhafrah ICLDC centre will be equipped with the latest diagnostic and management facilities and supported by a world-class multi-specialty team. It will operate state-of-the-art outpatient services and provide specialised care for diabetes and endocrine-related complications.
Dr. Mai Al Jaber, Chief Executive Officer of ICLDC, said:
"Today, the need for accessible and comprehensive diabetes care has never been more apparent. Serving more of the Al Dhafra population is an honour and a duty we are fully committed to. We aim to provide patients with the best patient-centric and comprehensive diabetes and endocrinology solutions under one roof and closer home."
The new clinic's journey will provide comprehensive services from registration to consultations and pharmacy support.